Canada · Delayed Price · Currency is CAD Knight Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Record Q1 2026 revenues and adjusted EBITDA were driven by portfolio expansion, strong promoted product growth, and multiple new launches. Fiscal 2026 guidance was raised, supported by robust cash flow, a strengthened balance sheet, and continued focus on acquisitions.
-
Record revenues and EBITDA were achieved in 2025, driven by acquisitions and product launches. All director nominees and auditors were approved, with a strong focus on growth in Canada and Latin America and disciplined capital allocation.
Fiscal Year 2025
-
Record 2025 results with CAD 452M revenue (+24% YoY) and CAD 73M adjusted EBITDA, driven by portfolio expansion and strong product launches. 2026 guidance targets CAD 490–510M revenue and continued launch momentum, with improved margins and cash position.
Fiscal Year 2024
-
Record revenues and strong portfolio growth were achieved despite currency headwinds and increased operating expenses. Guidance for 2024 is maintained, with new product launches and a robust pipeline expected to drive future growth.
-
Record Q2 revenue and EBITDA growth driven by promoted products and new launches, with raised 2024 guidance reflecting strong pipeline progress and favorable currency trends. Cash position remains robust, and disciplined M&A continues to offset generic pressure.